The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
No Access

Caffeine versus methylphenidate and d-amphetamine in minimal brain dysfunction: a double-blind comparison

Published Online:https://doi.org/10.1176/ajp.132.8.868

The authors compared the efficacy of caffeine, methylphenidate, and d- amphetamine in children with minimal brain dysfunction using a double- blind crossover design. The slight improvement with caffeine was not significantly better than placebo. Both prescription drugs resulted in significant improvement and were significantly superior to caffeine. The authors suggest that the discrepancy between these results and an earlier, more optimistic report mat stem from the use in this study of pure caffeine rather than whole coffee.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.